Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Invests $23.92 Million in Mineralys Therapeutics, Inc. $MLYS

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) in the 4th quarter, Holdings Channel.com reports. The firm bought 659,076 shares of the company’s stock, valued at approximately $23,918,000. Mineralys Therapeutics comprises 2.1% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s portfolio, making the stock its 18th largest holding.

Several other hedge funds also recently made changes to their positions in MLYS. AQR Capital Management LLC acquired a new stake in shares of Mineralys Therapeutics in the 1st quarter worth $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Mineralys Therapeutics by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Mineralys Therapeutics by 166.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after acquiring an additional 186,480 shares during the period. Woodline Partners LP acquired a new stake in shares of Mineralys Therapeutics in the 1st quarter worth $757,000. Finally, Creative Planning acquired a new stake in shares of Mineralys Therapeutics in the 2nd quarter worth $336,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $26.27, for a total transaction of $1,970,250.00. Following the completion of the transaction, the chief executive officer owned 705,051 shares in the company, valued at approximately $18,521,689.77. The trade was a 9.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the transaction, the director directly owned 6,200 shares of the company’s stock, valued at approximately $155,000. This represents a 32.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 153,772 shares of company stock worth $4,121,668. 18.94% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have recently commented on MLYS shares. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Bank of America raised their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Jefferies Financial Group reiterated a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating for the company. Finally, Wall Street Zen cut shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.33.

Mineralys Therapeutics Trading Down 1.7%

Shares of MLYS opened at $23.76 on Thursday. The stock has a market cap of $1.96 billion, a P/E ratio of -11.59 and a beta of 0.57. The company has a 50-day moving average of $27.94 and a two-hundred day moving average of $30.78. Mineralys Therapeutics, Inc. has a 12-month low of $12.59 and a 12-month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. As a group, analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.